trial

Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)

NCTId NCT01244828
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 157 (actual)
Sponsored by Organon and Co
Primary completion 2014-08-21
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
157 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2011-04-05
Primary completion
2014-08-21
Eligibility
ALL · 20 Years

Interventions & indications

Drugs
Asenapine

Sponsors

Organon and CoLead Sponsor

Sites

0 total

Linked catalysts

1
Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Mu — primary completion2014-08-21

Facts & assertions

4 sourced
Enrollment
157
Phase
PHASE3
Primary Completion Date
2014-08-21
Status
COMPLETED
relationships
The graph out of here
drug
Asenapine
drug
lead_sponsor
Organon and Co
company
indication
Schizophrenia
indication
Schizophrenia
indication